News & Events Summary of Results: Laboratory Analysis of Electronic Cigarettes Conducted By FDA FDA conducted a preliminary analysis on some samples of electronic cigarettes and components from two leading brands.Due to the variability among products, this analysis should not be used to draw conclusions about what substances are or are not present in particular electronic cigarettes or brands of electronic cigarettes.FDA's Center for Drug Evaluation, Office of Compliance purchased two samples of electronic cigarettes and components from two leading brands.These samples included 18 of the various flavored, nicotine, and no-nicotine cartridges offered for use with these products.These cartridges were obtained in order to test some of the ingredients contained in them and inhaled by users of electronic cigarettes.FDA's Center for Drug Evaluation, Division of Pharmaceutical Analysis (DPA) analyzed the cartridges from these electronic cigarettes for nicotine content and for the presence of other tobacco constituents, some of which are known to be harmful to humans, including those that are potentially carcinogenic or mutagenic.DPA's analysis of the electronic cigarette samples showed that the product contained detectable levels of known carcinogens and toxic chemicals to which users could potentially be exposed.DPA's testing also suggested that quality control processes used to manufacture these products are inconsistent or non-existent.Specifically, DPA's analysis of the electronic cigarette cartridges from the two leading brands revealed the following: Diethylene glycol was detected in one cartridge at approximately 1%.

Diethylene glycol, an ingredient used in antifreeze, is toxic to humans.Certain tobacco-specific nitrosamines which are human carcinogens were detected in half of the samples tested.Tobacco-specific impurities suspected of being harmful to humans—anabasine, myosmine, and β-nicotyrine—were detected in a majority of the samples tested.The electronic cigarette cartridges that were labeled as containing no nicotine had low levels of nicotine present in all cartridges tested, except one.Three different electronic cigarette cartridges with the same label were tested and each cartridge emitted a markedly different amount of nicotine with each puff.e cigarette bay areaThe nicotine levels per puff ranged from 26.8 to 43.2 mcg nicotine/100 mL puff.One high-nicotine cartridge delivered twice as much nicotine to users when the vapor from that electronic cigarette brand was inhaled than was delivered by a sample of the nicotine inhalation product (used as a control) approved by FDA for use as a smoking cessation aid.ecigarette bio

WASHINGTON — On Monday, Sen.Ron Johnson, chairman of the Senate Homeland Security and Governmental Affairs Committee, sent a second letter to the Food and Drug Administration (FDA) inquiring about new e-cigarette regulations, a follow-up to his previous letter to FDA Commissioner Robert M. Califf on May 17, 2016.e cigarette arrache la gorgeJohnson is raising concerns about the agency’s recent e-cigarette regulation, which could create undue burdens on small businesses and possibly lead to negative unintended health consequences.e cigarette des moines“Since I sent my initial letter to you, I have heard from many small-business owners who manufacture or sell e-cigarette products,” Johnson wrote in the letter.e cigarette coupons walgreens

These job creators have contacted my office expressing their grave concerns about the FDA’s regulatory overreach.They fear that the FDA’s e-cigarette rule will force them out of business by requiring them to complete costly and time-consuming premarket applications for each e-cigarette product.e-cigarette david lettermanIn addition, a large number of individuals have contacted my office to tell their stories about how they use or have used e-cigarettes to quit smoking.They do not want the FDA to make access to e-cigarettes more difficult for them—or others like them—as they fight to kick an addiction to smoking.” The letter can be found here and below: The Honorable Robert M. Califf, MD Commissioner U.S.Food and Drug Administration The Senate Committee on Homeland Security and Governmental Affairs is continuing to examine the U.S.Food and Drug Administration’s (FDA) recent regulation that expands its authority over e-cigarettes.

On May 17, 2016, I wrote to request your assistance in understanding the consequences that this new regulation may have on small businesses and the public’s health.To date, you have not responded to my letter.Therefore, I write again to reiterate my request for information about FDA’s regulation and its potential consequences.I requested that the FDA provide data on the number of e-cigarette businesses that will be affected by the rule.I also asked the FDA whether it would issue a revised rule if sufficient data demonstrate that e-cigarettes are a safer alternative to traditional cigarettes.Further, I questioned the FDA about the potential unintended consequences of its rule that may result in decreased access to e-cigarettes and increased consumption of traditional cigarettes.Since I sent my initial letter to you, I have heard from many small-business owners who manufacture or sell e-cigarette products.They do not want the FDA to make access to e-cigarettes more difficult for them—or others like them—as they fight to kick an addiction to smoking.